SomaLogic CEO Roy Smythe joins Colorado BioScience Association’s Board of Directors

BOULDER, Colo. (May 12, 2021)—The Colorado BioScience Association (CBSA) recently announced that SomaLogic Chief Executive Officer Roy Smythe was among the seven new members appointed to its board of directors. These new members were selected for their leadership at companies of all stages of commercialization and have expertise in issues that impact Colorado’s life sciences community. These new board members will serve a three-year term on CBSA’s board.

“SomaLogic has been an active member in CBSA for many years and I’m excited to be participating as a member of their board,” said SomaLogic’s CEO Roy Smythe. “Our company is at an important stage in our commercialization and supporting the life sciences community in Colorado is one of the ways we’re making sure our state continues to be a vibrant and innovative place for bioscience.”

Board members work in partnership with CBSA staff to support the growth of Colorado’s more than 720 life sciences companies. CBSA champions a collaborative life sciences ecosystem and advocates for a supportive business climate.

###

About SomaLogic
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary, and personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

SomaSignal™ tests are developed and performance characteristics determined by SomaLogic, Inc., and SomaLogic is a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.

SomaSignal™ tests have not been cleared or approved by the US Food and Drug Administration.

Forward Looking Statements Disclaimer

Certain matters discussed throughout this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, our use of words such as “expect,” “anticipate,” “believe,” “should,“ “estimate,” “intend,” “strategy,” “future,” “opportunity,” “will,” “forecast,” “plan,” “project,” “assume” or similar words of futurity identify such forward-looking statements. These forward-looking statements are based on current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such statements may relate to projections of the Company’s revenue, earnings and other business plans, financial and operational measures, Company debt levels, ability to repay outstanding indebtedness, payment of dividends, and future operations, among other matters. We caution you not to place undue reliance on any such forward-looking statements. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Forward-looking statements speak only as of the date they are made. You are cautioned not to put undue reliance on forward-looking statements.

SomaLogic Contact
Emilia Costales
720-798-5054
[email protected]

Sign up to receive our news releases